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Abstract
Background: Obesity may establish a crucial barrier for effective fertility treatment
in polycystic ovary syndrome (PCOS) females.
Objective: To compare results of intra-cytoplasmic sperm injection (ICSI) in
females with and without polycystic ovarian syndrome and further appraise the
effect of obesity in PCOS females.
Materials and Methods: A cross-sectional study from June 2015 to July 2016
included non-PCOS and PCOS (recognized by Rotterdam criteria) females who
underwent ICSI. The PCOS were further stratified into non-obese and Obese
according to the South Asian criteria for body mass index. Results were categorized
on the basis of beta-human chorionic gonadotropin (β-hCG) and transvaginal scan
into non-pregnant (β-hCG <25 mIU/ml), preclinical abortion (β-hCG >25 mIU/ml
with no fetal cardiac activity) and clinical pregnancy (β-hCG >25 mIU/ml with fetal
cardiac activity on transvaginal scan). In addition, reproductive outcomes;
implantation rate, clinical pregnancy rate and miscarriage rate among obese and
non-obese PCOS and non-PCOS patients were compared.
Results: Our results revealed 38.5% clinical pregnancy rate in non-PCOs females,
23.8% in non-obese PCOS females whereas 26.4% in obese PCOS. Preclinical
abortions were found to be highest (31.5%) in non-obese PCOS females and were
the lowest (26.2%) in non-PCOS females. In non-PCOS group and non-obese PCOS
females 35.4% and 44.6%, respectively, failed to become pregnant.
Conclusion: The success after ICSI in terms of number of clinical pregnancies was
more in non-PCOS patients as compared to PCOS. Increase in body mass index
reflected a negative impact on the reproductive outcome in PCOS patients.
Key words: Quetelet’s index, Obesity, Polycystic ovary syndrome, Sperm injection,
Intracytoplasmic, Infertility.

Introduction

P

olycystic ovary syndrome (PCOS) is
found in 6-10% of the general
population and considered to be a
common hormonal disorder in females of
reproductive age (1). According to the
Rotterdam criteria, females suffering from
PCOS have decreased or no ovulation,
excessive androgen secretion and ultrasound
evidence of poly cystic ovaries (2). More than
10 follicles, encircling an echo-dense stroma,
measuring 2-8 mm in diameters, contained in
an ovary sizing more than 10 CC in volume is
diagnostic of PCOS on ultrasound. PCOS is
manifested as changes in hormonal,
reproductive
and
metabolic
functions.
Reproductive and hormonal disorders of

PCOS include hypergonadism, anovulation,
and increased secretion of Luteinizing
hormone (LH) and early miscarriage risk.
Metabolic disorders of PCOS include
hyperinsulinemia, type 2 diabetes, obesity and
hyperlipidemia. PCOS hormonal imbalances
leading to anovulation is a significant cause of
infertility (2).
Primary infertility is found to be highly
prevalent in South Asia, particularly in
Pakistan with an estimated rate of 3% while
secondary infertility in Pakistan is 18.4%
Infertility,
specifically
associated
with
anovulation, is initially treated with antiestrogen clomiphene citrate and exogenous
gonadotropins.
Unfortunately,
this
can
increase the risk of multiple pregnancy rates,
therefore many patients are given assisted
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reproductive treatment (ART) comprising of in
vitro fertilization (IVF) and intra-cytoplasmic
sperm injection (ICSI) (3). ICSI is a highly
developed micromanipulation technique in
which a single sperm is injected into an egg in
vitro using micro-injectors (4). Obesity may
establish a crucial barrier for effective fertility
treatment in females who are PCOS. The
relationship of PCOS and ICSI outcome has
been the subject of observational studies.
Obese females with PCOS had less number
of retrieved oocytes and clinical pregnancy
rates with a higher rate of abortions (5). In
contrast, some studies suggested that obese
and non-obese PCOS patients revealed no
significant differences in IVF/ICSI results (6).
This study aimed to assess the ICSI
outcome in obese and non-obese women with
PCOS by comparing the number of retrieved
oocytes, implantation rate, clinical pregnancy
rate and miscarriage rates.

Materials and methods
A cross sectional study was conducted
from June 2015 till July 2016. The sample size
was calculated in Open Epi software version 3
based on the formula; n= [DEFF*Np(1-p)]/
[(d2/Z21-α/2*(N-1) +p*(1-p)]. We required a
sample size of 246 patients in order to
achieve a confidence interval of 95% with a
20% prevalence of PCOS. Despite the sample
size being 246, we surveyed 286 females to
cover the drop-outs which can occur during
the course of treatment. PCOS group was
further classified into Non-Obese PCOS (body
mass index (BMI <25 kg/m2, 130 females) and
91 females in Obese PCOS group (BMI ≥25
kg/m2).
The clinical examinations monitored
principles of Declaration of Helsinki. Females
with primary infertility for at least for 2 yr, age
range 20-40 yr and normal uterine cavity
assessed on ultrasound, hysterosalpingogram
or hysteroscopy were included. The first fresh
IVF-embryo transfer cycle with long down
regulation
protocol
was
taken
into
consideration. Exclusion criteria consisted of
females with known metabolic disorders
(Diabetes,
Hypertension,
Metabolic
Syndrome),
pelvic
pathologies
(hydrosalpinges, myoma etc.), presence of
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stage IV (severe) endometriosis, and past
history of myomectomy. All the cases that
developed hyper stimulation were not included
irrespective of the fact that cycle was
canceled or not. PCOS was diagnosed by
Rotterdam criteria; females who had
decreased or no ovulation, excessive
androgen secretion and ultrasound evidence
of PCO were selected (2).
The baseline investigations included
measurement of BMI on the basis of South
Asian Criteria (normal weight: 18.0-22.9
kg/m2, overweight: 23.0-24.9 kg/m2, obese:
≥25.0 kg/m2) (7); day 3 follicle stimulating
hormone (FSH) and antral follicle count done
by transvaginal scan (TVS). The treatment
protocol of females from down regulation,
controlled ovarian stimulation, ovulation
induction (OI), oocyte pick up and embryo
transfer was carried out as mentioned (8). The
preovulatory follicle count (PFC) and
endometrial thickness were measured on OI
day. On the basis of beta-human chorionic
gonadotropin (β-hCG) done 2 wk after egg
collection and TVS performed after another 2
wk after identification of clinical pregnancy
from pre-clinical abortion.
On the basis of β-hCG and TVS, results
were categorized into non-pregnant with βhCG <25 mIU/ml and preclinical abortion βhCG >25 mIU/ml with no fetal cardiac activity
on TVS. Clinical pregnancy was identified by
the existence of a gestational sac with cardiac
movement perceived by TVS. Oocyte
recovery rate was number of oocytes obtained
in comparison with visible follicles on TVS (9).
Fertilization rate was determined by formation
of pronuclei from the microinjected oocytes.
The implantation rate was determined by
appearance gestational sacs on TVS with
respect to number of transferred embryos
(10). A pregnancy rate was estimated by
existence of an intrauterine gestational sac on
TVS; per number of patients in the cycle (9).
Ethical consideration
Ethical approval was obtained from the
Institutional Review Board of Islamabad Clinic
Serving Infertile Couples (256-ICSFC-REC16). Informed written consent was obtained
from every participant.
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Statistical analysis
Computational data was stored and
analyzed by employing SPSS software
(Statistical Package for the Social Sciences,
version 21.0, SPSS Inc., Chicago, IL, USA).
Quantitative variables were computed for
Mean±SD. Analysis of Variance (ANOVA) with
Tukey’s HSD test was applied for post-hoc
analysis, and significance at p-value of 0.05.

Results
Out of an aggregate of 286 infertile females
undergoing ICSI procedure included in data
analysis, 65 (22.7%) were normal females
(non-PCOS group) and 221 (77.3%) were
PCOS females. Of the 221 PCOS females,
130 were included in non-obese PCOS group
(BMI <25) and 91 females were included in
obese PCOS group (BMI ≥25). Mean±SD of
oocyte parameters of the 3 groups are
summarized in Table I. The three groups did
not differ with regards to age. PFC and
number of oocytes/patient were found to be
higher in obese PCOS group. The quality of
embryos was graded as good (Grade I), fair
(Grade II) and poor (Grade III) on the basis of
cleavage rate and differentiation before
embryo replacement. Good quality embryo
with blastomeres of same size, slight or no
fragmentation, and a zona pellucida that is not
enormously dense in appearance; fair with
blastomeres of same size, little fragments in
cytoplasm wrapping <10% of embryo. Poor
quality embryo had blastomeres of noticeably

uneven size and moderate-to-significant
fragments of cytoplasm, wrapping >10% of
embryo external (11)
The number of fertilized oocytes, number of
cleaved embryos and grade 1 embryos were
more in non-PCOS group as compared to
non-PCOS group (Table I). Endometrial
thickness did not differ widely among the three
groups. Basal progesterone was significantly
low (9.69±3.66 ng/ml) in non-obese PCOS
females. Progesterone on OI day and
estradiol on day of ovulation were found to be
lower in non-obese PCOS females.
Table II compares the reproductive
outcomes in the three groups. Fertilization
rate and cleavage rate were the lowest in
obese PCOS females and were the highest in
non-PCOS females. Implantation rate was
significantly high (62.31±32.31) in non-PCOS
group
compared
to
obese
PCOS
(26.37±38.01) and non-obese PCOS group
(23.46±39.79).
Table III compares the pregnancy
outcomes among the three groups. 38.5% of
the non-PCOS females achieved clinical
pregnancies whereas only 23.8% non-obese
PCOS females achieved clinical pregnancies.
Similarly, preclinical abortions were found to
be highest (31.5%) in non-obese PCOS
females and were the lowest (26.2%) in nonPCOS females. 44.6% non-obese PCOS
females never got pregnant while only 35.4%
non-PCOS females failed to get pregnant.

Table I. Comparison of characteristics of study groups
Variables

PCOS (n= 221)
Obese (n=91)
Non-Obese (n=130)
32.02 ± 4.81
32.42 ± 4.45
10.86 ± 1.66
9.28 ± 1.57
9.86 ± 1.66
8.45 ± 1.71
6.71 ± 1.09
7.07 ± 1.62
4.35 ± 1.03
4.88 ± 1.33
3.89 ± 1.3
4.45 ± 1.5
0.99 ± 0.1
1.59 ± 0.49
1.9 ± 0.34
1.95 ± 0.57
1.65 ± 0.77
1.32 ± 0.47
8.8 ± 3.2
8.05 ± 3.24
14.17 ± 7.65
9.69 ± 3.66
1.64 ± 0.74
1.46 ± 0.76
146.43 ± 63.51
154.37 ± 58.95
2342.71±243.0
2139.43±411.7
891.27±119.39
856.07±173.86

Female age (yr)
Pre-ovulatory follicle count
No of oocytes/patient
No of oocytes Metaphase II
No of oocytes fertilized
No of cleaved embryos
Grade_1
Grade_2
Grade_3
Endometrial thickness (mm)
Basal progesterone (ng/ml)
Progesterone on ovulation induction day (ng/ml)
Progesterone on embryo transfer day (ng/ml)
Estradiol on ovulation induction day (pg/ml)
Estradiol on embryo transfer day (pg/ml)
Data presents values as Mean±SD.
ANOVA test was applied to calculate difference between groups and p <0.001 was considered significant.
PCOS: Polycystic ovary syndrome
*p value <0.05, non PCOS with non-obese PCOS
^ p value <0.05, non PCOS with obese PCOS

Non-PCOS (n=65)

p-value

31.34 ± 4.63
8 ± 1.61*^
7.86 ± 1.54*^
7.52 ± 1.64^
6.03 ± 1.55*^
5.68 ± 1.53*^
2.71 ± 0.76*^
1.68 ± 0.56*^
0.74 ± 0.54*^
8.14 ± 3.63
14.3 ± 9.39*
1.55 ± 0.68*^
137.62±64.11*^
2267.2±243.6^
881 ± 115.54^

0.302
<0.001
<0.001
0.004
<0.001
<0.001
<0.001
0.001
<0.001
0.231
<0.001
0.220
0.195
<0.001
0.188
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Table II. Comparison of reproductive outcome in PCOS and non-PCOS
PCOS (n= 221)
Obese (n=91)
Non-Obese (n=130)
Oocytes retrieval rate
90.58 ± 1.38
90.7 ± 4.43
Oocyte maturity rate
69.059
83.800
Fertilization rate
64.64 ± 10.05
68.17 ± 5.62
Cleavage rate
87.67 ± 16.55
91.26 ± 17.72
Implantation rate
26.37 ± 38.01
23.46 ± 39.79
Data presents values as frequencies in percentages using the following formulas.
Oocyte retrieval rate= Number of Oocytes/ PFC ×100 (PFC: preovulatory follicle count)
Oocyte Maturity rate= Number of mature oocytes=Mature oocytes/ number of oocytes ×100
Fertilization rate= Pronuclei/ mature oocytes ×100
Cleavage rate= Cleaved embryo/ fertilized embryo ×100
Impanation rate= Number of sacs/ number of embryos transferred×100
*p value <0.05, non PCOS with non-obese PCOS
^ p value <0.05, non PCOS with obese PCOS
Rates

Non PCOS (n=65)

p-value

98.54 ± 4.78*^
95.504*^
79.61 ± 10.59*^
94.42 ± 7.68*^
62.31 ± 32.31*^

<0.001
<0.001
<0.001
0.028
<0.001

Table III: Outcome after ICSI in study Groups
Pregnancy

PCOS (n= 221)
Non-Obese (n= 130)
42.9
30.8
26.4

Not pregnant
Preclinical abortion
Clinical pregnancies
Data presented as percentage.
PCOS: Polycystic ovary syndrome
*p value <0.05, non PCOS with non-obese PCOS
^ p value <0.05, non PCOS with obese PCOS

Discussion
Results of current research revealed that
clinical pregnancies rate was highest in nonPCOS females followed by non-obese PCOS
and then obese PCOS. Similarly, preclinical
abortions were found to be maximum in nonobese PCOS females and lowest in nonPCOS females. Around 44.6% non-obese
PCOS females never got pregnant while only
35.4 % non-PCOS females failed to get
pregnant in the study. Although the effect of
BMI
on
IVF/ICSI
outcomes
remain
controversial due to different inclusion criteria
and the cutoff point of BMI yet we discovered
that increase in BMI effected the pregnancy
outcome in PCOS patients.
PCOS females experiencing fertility
management have a much higher possibility
of multiple pregnancies and other adverse
complications as a result of ovarian
hyperstimulation. Due to the failure of less
invasive techniques, IVF/ICSI is deliberated
as best treatment choice intended to restore
fertility whereas minimizing the chance of
multiple gestations. The association of obesity
with PCOs has been observed in 30-75% of
females (12). Recent data proposes that,
irrespective of PCOS, pregnancy attainment
and preservation is poorly pretentious by an
increase in BMI. Obese women thus
experience lesser options of
clinical
pregnancy with an increased miscarriage rate
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Obese (n= 91)
44.6
31.5
23.8

Non-PCOS (n= 65)
35.4*^
26.2*^
38.5*^

after getting infertility management. In our
study, we found that PFC was higher in PCOS
groups and lower in non-PCOS group. This is
attributed to hormonal disturbances in PCOS
females resulting in the development of
multiple small follicles that do not ovulate each
month. Others have previously reported
similar results (13).
Ciepiela and coworkers also found that the
number of follicles, as well as oocytes, was
higher in PCOS group even at a lower dose of
gonadotropins (14). Number of oocyte per
patient was found to be higher in PCOS
groups and lower in non-PCOS group
confirming previous studies. It has been
observed that obesity, as well as presence of
PCOS, results in reduction in size of oocytes
(15, 16). Increased number of MII oocytes is
associated with positive ICSI outcomes (8).
MII oocytes were found to be the highest in
non-PCOS group in our study. Similar results
were found in previous studies (15).
Some studies have shown higher number
of MII oocytes in PCOS females but this was
mainly due to the fact that PCOS females
develop greater number of oocytes. In these
studies, percentage of MII oocytes was still
higher in non-PCOS females (14). Our results
showed a negative association is existed
between MII oocytes with BMI supported by
others (13). Number of fertilized oocytes was
found to be lowest in obese PCOS group and
lower in non-Obese PCOS group. In contrast,
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other studies showed increased number of
oocytes were fertilized in PCOS females (14).
However, Hind and colleagues proposed that
BMI and PCOS have no significant effect on
the number of oocytes fertilized (17). There is
an increased incidence of pregnancy loss in
PCOS as a result of the inborn endocrine
disruption linked to the syndrome (18).
Our results revealed that rate of clinical
pregnancy in non-PCOS females was 38.5%
whereas it was 23.8% in non-Obese PCOS
females. Similarly, preclinical abortions were
found to be highest (31.5%) in Obese PCOS
females and were the lowest (26.2%) in nonPCOS females. Our data revealed that the
clinical pregnancy rate in non-PCOS females
was higher whereas failure of pregnancy was
highest in Obese PCOS females. The
negative impact of increase in weight on the
quality of oocyte without PCOS has been
documented by a decrease in number of
transferable embryos in obese, females. A
subgroup enquiry discovered smaller oocytes
in the obese control patients compared to the
non-obese control infertile patients proposing
that obesity affects oocyte size independent of
PCOS. (15) Our results demonstrated that
preclinical abortions were found to be highest
(31.5%) in obese PCOS females and were the
lowest (26.2%) in non-PCOS females. Some
scientists concluded in their study that, the
presence of PCOS in non-obese patient may
be a favorable prognostic factor before
considering IVF (14).
Wang and colleagues emphasized that in
young PCOS females (less than 25 yr of age)
BMI should be reduced to 26 kg/m2 before
initiation of ART (16, 19). Overweight and
obese PCOS patients should thus be
encouraged to lose weight before initiation of
ART (6). It was observed that BMI impaired
endometrial
receptivity
in
assisted
reproductive treatment protocols (16, 20)
Higher implantation and pregnancy rates were
acquired with an endometrial thickness of 7-8
mm in our population (21). However, we did
not observe any significant difference in
endometrial thickness in PCOS and nonPCOS to impact on pregnancy outcome.
Okohue observed likelihood of becoming
pregnant with endometrial thickness 8-14 mm
(22). The number of clinical pregnancies
acquired after ICSI was high in non-PCOS
patients as compared to PCOS. Increase in
BMI of PCOS exerted a dual effect, decreased

the number of clinical pregnancies and
enhanced the number of non-conceptions and
pre-clinical abortions. Our study did not
exclude the females who had infertility
because of male factor, since we wanted to
compare results of ICSI in females with and
without PCOS, hence impact of severe male
factor on IVF outcome could not be excluded
which is a limitation. Thus it is recommended
to induce weight reduction strategies for
PCOS patients before initiation of ART for
enhancing the results of IVF/ICSI.
The success after ICSI in terms of number
of clinical pregnancies was more in nonPCOS patients as compared to PCOS.
Increase in body mass index reflected a
negative impact on the reproductive outcome
in PCOS patients. Since PCOS is mostly
occurred with obesity, it is essential to
decrease weight in PCOS patients for
attainment of improved outcomes of IVF/ICSI.
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